A compound that is represented by the following Formula III: wherein: R 1 has the formula C 1-5 alkylene-L-R 1-1, wherein: the C 1-5 alkylene is interrupted with one -O- group, and wherein alkylene includes straight chain, branched chain, and cyclic groups; L is a bond or a functional linking group selected from the group consisting of -NH-S 2 -, -NH-C -, -NH-C -, -NH-S 2 -NR 3 -, -NH-C -NR 3 -, -NH-C -NR 3 -, -NH-C -O-, -O-, -S-, and -S 2 -; and R 1-1 is a linear or branched aliphatic group having at least 11, carbon atoms, optionally including one or more unsaturated carbon-carbon bonds; R is selected from the group consisting of halogen, hydroxy, alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and -N(R 3) 2; R 3 is selected from the group consisting of hydrogen and alkyl; n is 0 to 4; R 2 is selected from the group consisting of: hydrogen; alkyl; alkenyl; aryl; heteroaryl; heterocyclyl; alkylene-Y-alkyl; alkylene-Y-alkenyl; alkylene-Y-aryl; and alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: -OH; halogen; -N(R 4) 2; -C -C 1-10 alkyl; -C -O-C 1-10 alkyl; -N 3; aryl; heteroaryl; heterocyclyl; -C -aryl; and -C -heteroaryl; Y is -O- or -S 0-2 -; each R 4 is independently selected from the group consisting of hydrogen, C 1-10 alkyl, and C 2-10 alkenyl; and with the proviso that when L is -NH-S 2 -, and n is 0, R 1-1 is a linear or branched aliphatic group having greater than 16 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds; or a pharmaceutically acceptable salt thereof. R 1 has the formula C 1-5 alkylene-L-R 1-1, wherein: the C 1-5 alkylene is interrupted with one -O- group, and wherein alkylene includes straight chain, branched chain, and cyclic groups; L is a bond or a functional linking group selected from the group consisting of -NH-S 2 -, -NH-C -, -NH-C -, -NH-S 2 -NR 3 -, -NH-C -NR 3 -, -NH-C -NR 3 -, -NH-C -O-, -O-, -S-, and -S 2 -; and R 1-1 is a linear or branched aliphatic group having at least 11, carbon atoms, optionally including one or more unsaturated carbon-carbon bonds; the C 1-5 alkylene is interrupted with one -O- group, and wherein alkylene includes straight chain, branched chain, and cyclic groups; L is a bond or a functional linking group selected from the group consisting of -NH-S 2 -, -NH-C -, -NH-C -, -NH-S 2 -NR 3 -, -NH-C -NR 3 -, -NH-C -NR 3 -, -NH-C -O-, -O-, -S-, and -S 2 -; and R 1-1 is a linear or branched aliphatic group having at least 11, carbon atoms, optionally including one or more unsaturated carbon-carbon bonds; R is selected from the group consisting of halogen, hydroxy, alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and -N(R 3) 2; halogen, hydroxy, alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and -N(R 3) 2; R 3 is selected from the group consisting of hydrogen and alkyl; n is 0 to 4; R 2 is selected from the group consisting of: hydrogen; alkyl; alkenyl; aryl; heteroaryl; heterocyclyl; alkylene-Y-alkyl; alkylene-Y-alkenyl; alkylene-Y-aryl; and alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: -OH; halogen; -N(R 4) 2; -C -C 1-10 alkyl; -C -O-C 1-10 alkyl; -N 3; aryl; heteroaryl; heterocyclyl; -C -aryl; and -C -heteroaryl; hydrogen; alkyl; alkenyl; aryl; heteroaryl; heterocyclyl; alkylene-Y-alkyl; alkylene-Y-alkenyl; alkylene-Y-aryl; and alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: -OH; halogen; -N(R 4) 2; -C -C 1-10 alkyl; -C -O-C 1-10 alkyl; -N 3; aryl; heteroaryl; heterocyclyl; -C -aryl; and -C -heteroaryl; -OH; halogen; -N(R 4) 2; -C -C 1-10 alkyl; -C -O-C 1-10 alkyl; -N 3; aryl; heteroaryl; heterocyclyl; -C -aryl; and -C -heteroaryl; Y is -O- or -S 0-2 -; each R 4 is independently selected from the group consisting of hydrogen, C 1-10 alkyl, and C 2-10 alkenyl; and